Seek Returns

Vaxcyte (PCVX) Stock Analysis

This is a peer-relative look at Vaxcyte (PCVX): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Company profile fields for Vaxcyte (PCVX)
Profile ItemPCVX
NameVaxcyte Inc.
Country/RegionUnited States
GICS SectorHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
GICS Sub-IndustryBiotechnology
Market Capitalization10.11 billion USD
CurrencyUSD
ExchangeNasdaq
Listing DateJune 12, 2020
Security TypeCommon Stock

Price Performance

Cumulative Growth

PCVX
GSPC
Loading price history…
Vaxcyte (PCVX) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Vaxcyte (PCVX) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Vaxcyte (PCVX) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Vaxcyte (PCVX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: PCVXIndustry group median
Total Return (1Y)59.00%24.62%
Total Return (3Y, Annualized)11.29%20.37%
Total Return (5Y, Annualized)21.60%-4.02%

Risk Profile

Drawdown History

PCVX
GSPC
Loading price history…
Vaxcyte (PCVX) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Vaxcyte (PCVX) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Vaxcyte (PCVX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: PCVXIndustry group median
Volatility (1Y, Annualized)56.01%66.36%
Beta (5Y)1.260.93
Max Drawdown (5Y)-76.22%-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. PCVX is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

Vaxcyte (PCVX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: PCVXIndustry group median
Sharpe Ratio (1Y)0.980.36
Sortino Ratio (1Y)1.760.58

Profitability

ROE (TTM)

Vaxcyte (PCVX) has negative ROE of -42.68%. That can come from trailing losses or negative book equity, so it is a warning state rather than a clean capital-efficiency measure.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Group distribution
Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%
Largest peers
LLY
86.02%
NVS
24.33%
AZN
22.57%
JNJ
20.02%
MRK
5.06%
PCVX
-42.68%
ABBV
--
Loading chart…
Where Vaxcyte (PCVX) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

Vaxcyte (PCVX) keeps 0.00% of revenue as net profit, roughly in line with the peer group’s normal net margin range. Its full cost stack is taking a typical share of sales for the industry.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution
Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Largest peers
LLY
31.90%
AZN
17.68%
NVS
17.49%
JNJ
16.20%
ABBV
15.67%
MRK
3.64%
PCVX
0.00%
Loading chart…
Where Vaxcyte (PCVX) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

Vaxcyte (PCVX) turns 0.00% of revenue into operating profit, roughly in line with the peer group’s normal operating margin range. Its core cost structure looks typical for the industry.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution
Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Largest peers
LLY
53.66%
ABBV
39.59%
MRK
35.22%
NVS
34.27%
AZN
29.57%
JNJ
25.74%
PCVX
0.00%
Loading chart…
Where Vaxcyte (PCVX) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

Vaxcyte (PCVX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: PCVXIndustry group median
ROE (TTM)-42.68%-26.66%
ROA (TTM)-24.98%-12.50%
Net Margin (TTM)0.00%0.00%
Operating Margin (TTM)0.00%0.00%
Gross Margin (TTM)0.00%37.87%

Growth

Revenue Growth

No usable revenue growth is available for Vaxcyte (PCVX) this period, so the top-line momentum read is skipped.

Loading chart…
Vaxcyte (PCVX) doesn't report Revenue Growth this period; the bars show the Pharmaceuticals, Biotechnology & Life Sciences industry-group medians on their own.

EPS Growth

No usable EPS growth is available for Vaxcyte (PCVX) this period, so the earnings-momentum read is skipped.

Loading chart…
Vaxcyte (PCVX) doesn't report EPS Growth this period; the bars show the Pharmaceuticals, Biotechnology & Life Sciences industry-group medians on their own.

Growth Metrics

Vaxcyte (PCVX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: PCVXIndustry group median
Revenue Growth (YoY)--11.45%
Revenue Growth (3Y CAGR)--9.94%
EPS Growth (YoY)--4.28%
EPS Growth (3Y CAGR)--4.17%

Financial Strength

Current Ratio (MRQ)

Vaxcyte (PCVX) has current ratio of 4.56, in the healthier middle range for its industry. The short-term asset cushion looks balanced relative to peers rather than stretched thin.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Group distribution
Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10
Largest peers
PCVX
4.56
LLY
1.39
MRK
1.35
JNJ
1.02
AZN
1.01
NVS
0.88
ABBV
0.87
Loading chart…
Where Vaxcyte (PCVX) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

Vaxcyte (PCVX) has debt-to-equity ratio of 0.09, roughly in line with the peer group’s normal leverage range. Its mix of debt and equity looks typical for the industry.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Group distribution
Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00
Largest peers
NVS
1.29
LLY
1.23
MRK
1.20
AZN
0.66
JNJ
0.55
PCVX
0.09
ABBV
--
Loading chart…
Where Vaxcyte (PCVX) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength Metrics

Vaxcyte (PCVX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: PCVXIndustry group median
Current Ratio (MRQ)4.565.52
Debt / Equity (MRQ)0.090.15
Net Debt / EBITDA--1.08

Dividends

Dividend Yield (TTM)

Vaxcyte (PCVX) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution
PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Largest peers
NVS
2.88%
ABBV
2.40%
MRK
2.29%
JNJ
1.94%
AZN
1.73%
LLY
0.49%
PCVX
0.00%
Loading chart…
Where Vaxcyte (PCVX) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

Vaxcyte (PCVX) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution
PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Largest peers
MRK
343.43%
ABBV
117.35%
NVS
90.46%
JNJ
80.12%
AZN
45.38%
LLY
21.71%
PCVX
0.00%
Loading chart…
Where Vaxcyte (PCVX) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

Vaxcyte (PCVX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: PCVXIndustry group median
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

No usable P/E ratio is available for Vaxcyte (PCVX) this period, so the trailing-earnings valuation read is skipped.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Group distribution
Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--
Largest peers
MRK
148.21
ABBV
50.05
LLY
43.95
JNJ
41.92
NVS
31.02
AZN
26.37
PCVX
--
Loading chart…
Vaxcyte (PCVX) doesn’t report P/E ratio this period; the box shows the Pharmaceuticals, Biotechnology & Life Sciences group’s distribution and the dots its largest members.

P/S Ratio (TTM)

No usable P/S ratio is available for Vaxcyte (PCVX) this period, so the revenue-based valuation read is skipped.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Group distribution
Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--
Largest peers
LLY
13.95
ABBV
7.80
JNJ
6.69
MRK
5.37
NVS
5.35
AZN
4.63
PCVX
--
Loading chart…
Vaxcyte (PCVX) doesn’t report P/S ratio this period; the box shows the Pharmaceuticals, Biotechnology & Life Sciences group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

Vaxcyte (PCVX) trades at 3.83 on P/B ratio, roughly in line with the industry’s normal price-to-book range. Its balance sheet is not being priced at a clear discount or premium versus peers.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Group distribution
Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59
Largest peers
LLY
29.96
NVS
8.25
JNJ
8.16
MRK
8.06
AZN
5.59
PCVX
3.83
ABBV
-112.34
Loading chart…
Where Vaxcyte (PCVX) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

Vaxcyte (PCVX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: PCVXIndustry group median
P/E Ratio (TTM)--26.69
P/S Ratio (TTM)--7.30
P/B Ratio (MRQ)3.833.25
Free Cash Flow Yield (TTM)-5.24%-1.66%